Suvaxyn CSF Marker


classical swine fever vaccine (live recombinant)

This medicine is authorised for use in the European Union.


Suvaxyn CSF Marker is a veterinary vaccine used to protect pigs against outbreaks of classical swine fever (CSF), a very severe and highly contagious viral disease of both wild and domestic pigs. This disease causes fever, skin lesions, convulsions and often leads to death of the animals. It is also used to protect breeding sows in order to reduce infection of their unborn piglets by classical swine fever virus (CSFV).

Suvaxyn CSF Marker contains live bovine viral diarrhoea virus (BVDV) which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of CSFV.

This EPAR was last updated on 03/12/2021

Authorisation details

Product details
Suvaxyn CSF Marker
Agency product number
Active substance
Live Recombinant E2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus E2 gene (CP7_E2alf)
International non-proprietary name (INN) or common name
classical swine fever vaccine (live recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

16/08/2021 Suvaxyn CSF Marker - EMEA/V/C/002757 - II/0009

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Live viral vaccines
  • Immunologicals for suidae

Therapeutic indication

For active immunisation of pigs from 7 weeks of age onwards to prevent mortality and reduce infection and disease caused by classical swine fever virus (CSFV).

Onset of immunity: 14 days after vaccination

Duration of immunity: at least 6 months after vaccination

For active immunisation of breeding females to reduce transplacental infection caused by CSFV.

Onset of immunity: 21 days after vaccination

Duration of immunity has not been demonstrated.

Assessment history

How useful was this page?

Add your rating